Spain's health authorities have confirmed 111 cases of a rare cancer associated with breast implants, according to the latest report from the Spanish Agency of Medicines and Medical Devices (Aemps). The figures, updated through 2025, are part of the sixth follow-up report on the national protocol for detecting and studying anaplastic large cell lymphoma linked to breast implants (BIA-ALCL). Since monitoring began in 2012, Aemps has received 146 suspected reports in total.
The data, drawn from the Medical Devices Vigilance System, underscores the ongoing collaboration between Aemps, medical societies, and European health authorities to track this condition. Madrid is the autonomous community with the highest number of reports, ahead of Andalusia, Catalonia, and the Valencian Community.
A Rare Cancer with a Specific Link
BIA-ALCL is an uncommon type of non-Hodgkin lymphoma. Unlike breast cancer, it does not originate in breast tissue but in immune system cells that can develop in the fibrous capsule surrounding the implant. Aemps stresses that this is a rare disease, with incidence remaining low relative to the large number of women with breast implants. Nevertheless, the agency emphasizes the importance of maintaining surveillance and improving early detection.
Research points to a multifactorial origin. Factors under investigation include the type of implant—particularly textured surfaces—certain genetic predispositions, and possible inflammatory processes or contamination associated with the implant. However, experts caution that no definitive causal relationship has been established, and the precise mechanism triggering the lymphoma remains unknown.
The findings align with broader European efforts to monitor medical device safety. For context, the European Union's Medical Device Regulation (MDR) has tightened requirements for implantable devices, including breast implants, since its full application in 2021. Spain's proactive reporting system reflects this regulatory shift, aiming to identify risks early.
While the absolute number of cases is small, the condition has drawn attention from health authorities across the continent. In recent years, similar cases have been reported in France, Germany, and the United Kingdom, prompting coordinated surveillance under the European vigilance system. The European Commission has also funded research into the long-term safety of medical implants.
For women considering or living with breast implants, the message from Aemps is one of caution without alarm. The agency recommends that women with textured implants remain aware of symptoms such as persistent swelling, pain, or lumps around the implant, and consult their healthcare provider if concerns arise. Routine monitoring and imaging can aid early detection.
Spain's report comes amid other health-related developments in the country. For instance, a recent study found that GLP-1 weight-loss drugs are linked to a 30% lower breast cancer risk, highlighting the intersection of pharmaceutical research and public health. Meanwhile, the country's startup ecosystem continues to grow, though talent abounds but funding and exit strategies lag, reflecting broader economic trends.
The Aemps report serves as a reminder of the importance of post-market surveillance for medical devices. As the European health community continues to gather data, the hope is that better understanding of BIA-ALCL will lead to improved prevention, diagnosis, and treatment. For now, the agency's vigilance remains a key tool in protecting patient safety across Spain and beyond.
